Physician surveys
Online and telephone studies (n=50–500+) across 17+ EMEA countries — NHS, private, and hospital settings.
Physician surveys · EMEA
Quantitative Healthcare Research & Physician Surveys
Large-scale statistical insights from physicians and healthcare professionals across UK, Europe, and MENA markets. Part of our healthcare market research programmes — statistically robust evidence for commercial, medical affairs, and market access teams.
Three cuts
The brief is not a country average
Trade-off design
Conjoint, MaxDiff, and discrete choice experiments sized to the cognitive load clinicians can actually complete.
Decision-ready cuts
Market sizing, tracking, HTA decision-maker insights, and payer willingness-to-pay — not a headline average alone.
Overview
Overview
BioNixus conducts rigorous quantitative healthcare market research designed to provide statistically robust evidence for pharmaceutical decision-making. Our physician surveys span multiple specialties and countries, delivering the data foundations your commercial, medical affairs, and market access teams need.
What we field
Capabilities
Online and telephone physician surveys (n=50–500+) across 17+ EMEA countries
NHS and private healthcare provider research in the UK
Hospital preference and formulary studies
Prescription tracking and treatment pattern analysis
Health Technology Assessment (HTA) decision-maker insights
Payer willingness-to-pay and budget impact studies
Multi-country surveys across UAE, Saudi Arabia, Egypt, Kuwait, Qatar
Conjoint analysis, MaxDiff, and discrete choice experiments (DCE)
Brand tracking and awareness studies
Market sizing, forecasting, and segmentation
What you receive
Deliverables
Statistical reports with confidence intervals and significance testing
Market sizing and revenue forecasting models
Treatment pathway and patient flow analysis
Competitive benchmarking dashboards
Cross-country comparative analysis
Segmentation and targeting recommendations
Where we field
UK, EU5, GCC, and North Africa
Geographic Coverage
UK (NHS England, Scotland, Wales, Northern Ireland), EU5 (Germany, France, Spain, Italy), GCC (UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman), and North Africa (Egypt, Morocco, Tunisia).
Service reference
Reference handbook: quantitative research healthcare research at BioNixus
A structured narrative for commissioning teams, procurement reviewers, consultancy partners, and machine-readable site synthesis—paired with pragmatic conversion pathways to speak directly with BioNixus principals.
Context: services hub · healthcare programmes · case evidence
Operational definition of "quantitative research" programmes at BioNixus
Within BioNixus, the quantitative research service line denotes a coherent decision architecture—not a templated commodity deliverable. Engagements anchor on explicit choices global and regional stakeholders must resolve: stakeholder prioritisation, evidence gaps, forecasting uncertainty, segmentation boundaries, omnichannel choreography, lifecycle defence investments, governance documentation requirements.
Each mandate begins with clarification of hypotheses, minimally sufficient granularity, permissible inference depth, analogous markets informing priors, and how outputs cascade into forecasting, KPI ownership, procurement reviews, alliance partner alignment.
Why quantitative research research must reconcile local behavioural realism
Markets diverge materially in autonomy, formulary stewardship, pharmacist substitution prevalence, linguistic nuance influencing interview candour, digital channel maturity, contractual confidentiality expectations, clustering of prescribing volume, payer adjacency—even when therapy areas appear identical.
Research that ignores these structural layers converts into attractive slide aesthetics without durable strategic leverage. BioNixus embeds calibrated local instrumentation while retaining comparability pillars for multinational governance.
Programme governance, sampling ethics, reproducibility artefacts
High-trust pharma research requires reproducible quotas, disciplined screenouts, verbatim traceability where permitted, audited translations, escalation logs for recruiting difficulties, versioning of questionnaires, reproducible dashboards, archiving sufficient for audits or alliance diligence.
BioNixus emphasises methodological transparency—not because sponsors enjoy paperwork, because uncertainty compounds when replication or longitudinal tracking becomes necessary eighteen months later after competitive shocks or guideline updates.
Cross-linking quantitative depth with qualitative forensics economically
Sequential hybrids often outperform parallel waste: quantify directionally first where uncertainty is broad, then selectively deepen qualitatively at fracture lines; or qualitative hypothesis generation feeding structured quant validation when segment hypotheses remain unstable.
Budget allocation should correlate with elasticity of pivotal decisions—not cosmetic comprehensiveness drowning insight teams in charts.
How sponsors convert quantitative research insights into KPI movements
Conversion requires explicit mapping from evidence statements to behavioural levers Medical Affairs adjusts, Brand recalibrates messaging tests for, Market Access reallocates dossier sequencing for, PSP teams friction-fix, Procurement anticipates tenders for—not generic “insights.”
BioNixus workshops optionally operationalise artefacts: segment playbooks with objection hierarchies; account tagging schemes; prioritized medical education arcs; stakeholder influence maps aligning KOL tiers to decisions relevant to uptake—not mere connectivity graphs.
Regional portfolio orchestration spanning MENA, UK, EU5 corridors
Multinational teams benefit when vendors harmonise taxonomy while respecting divergence: tender-led Saudi clusters differ from ICS-governed NHS flows; Emirates private acceleration diverges from Egypt public reform arcs; Italy regional variance diverges from Nordics consolidated procurement philosophies.
BioNixus reduces integration debt by aligning variable dictionaries, bridging segments carefully, resisting false uniformisation that erodes local credibility—or false fragmentation obscuring transferable lessons.
Sampling design, powering, quota integrity, elasticity diagnostics
Quant engagements emphasise powering aligned to subgroup decisions—not global headline significance theatrics meaningless if segments driving revenue remain unresolved. Adaptive quota choreography rescues timelines when recruiting friction spikes without silently biasing inference.
Trade-off methodologies (MaxDiff, DCEs) adhere to cognitive load budgets—avoiding factorial explosions clinicians abandon midstream; anchoring vignettes tether abstract attributes to wards, procurement scoring, stewardship rituals.
Forecast bridges stress-test elasticity of behavioural intent vs operational ceilings—preventing exaggerated adoption ramps.
Dashboarding for leadership consumption vs analytic audit depth
Deliverables bifurcate intentionally: concise leadership synthesis plus reproducible appendix layers satisfying analytics governance, alliance diligence, methodological peer review—all version controlled.
Executive calibration questions before commissioning BioNixus quantitative research work
Which decision materially changes within six to twelve months if evidence arrives? Which stakeholders wield veto unrecognized on org charts? What analogue trajectories constrain priors? What governance approvals gate field release? Which segments remain strategically decisive even if statistically uncomfortable to sample?
Arriving with calibrated answers—even provisional—elevates methodological sharpness materially.
Frequently asked questions
What does quantitative healthcare market research include?
Robust sampling frameworks, segmentation analytics, MaxDiff or discrete choice when trade-offs mirror real decisions, adoption metrics, and forecast bridges stress-testing elasticity of intent versus operational ceilings. BioNixus builds for decision use—not reporting volume alone.
How is statistical powering aligned to commercial decisions?
Powering targets subgroup decisions that move revenue and access—not global headline significance theatrics meaningless if decisive segments remain unresolved. Adaptive quota choreography rescues timelines when recruiting friction spikes without silently biasing inference.
When should conjoint or MaxDiff be used in pharma quant?
When messaging, device attribute, or tender scoring trade-offs must be ranked under cognitive load budgets clinicians can actually complete. BioNixus avoids factorial explosions that produce abandoned surveys and ornamental charts.
Can quantitative modules integrate with qualitative forensics?
Yes. Sequential hybrids quantify directionally first, then deepen qualitatively at fracture lines—or qual generates hypotheses quant validates when segments remain unstable. Budget follows elasticity of pivotal decisions, not cosmetic comprehensiveness.
What governance artefacts accompany quant deliverables?
Concise leadership synthesis plus reproducible appendix layers—questionnaire versioning, quota logs, dashboard codebooks—satisfying analytics governance and alliance diligence. See also our quantitative healthcare market research methodology guide on the main site.
How does BioNixus execute quant across MENA, UK, and EU5?
Harmonised variable dictionaries with local recruitment and language modules; field teams experienced in physician, pharmacist, and payer-adjacent quotas in priority healthcare markets.
How should quant sample design reflect payer-adjacent decisions?
When tender scoring or formulary stewardship shapes uptake, quant modules include pharmacist and procurement-adjacent quotas—not physician-only panels that miss substitution and scoring rituals. BioNixus aligns instrument length and trade-off design to cognitive load budgets each stakeholder type can realistically complete.
What is the typical timeline from scope to leadership-ready quant deliverables?
Timelines depend on quota complexity and hybrid sequencing, but engagements typically move from calibrated scope memo through field release, cleaning, segmented analytics, and governance-ready synthesis within planning cycles affiliates can align to launch gates—not open-ended tracker maintenance without decision owners.
Discuss Your Quantitative Research Needs
Tell us about your project and receive a tailored proposal within 24 hours.
What is quantitative healthcare market research and when does a pharma team need it?
Quantitative healthcare market research measures how many physicians, pharmacists, payers or patients hold a view or behave a certain way, with a sample large enough to report confidence intervals. Pharma and medtech teams commission it when a decision needs a number — share of patients eligible for a new therapy, the price at which prescribing intent falls, or the awareness-trial-usage funnel of a brand against its competitors. BioNixus fields physician, pharmacist and payer surveys across the GCC, Egypt, Turkey, the UK, EU5, the US and Asia with specialty-verified respondents and Arabic–English instruments.
- Specialty-verified samplesRespondents are screened on specialty, patient volume and institution type, then verified against registries and licence lists before they count toward quota.
- Decision-grade methodsConjoint, MaxDiff, discrete-choice, Van Westendorp and Gabor-Granger designs, TURF and segmentation, chosen for the decision rather than the deck.
- Multi-country comparabilityOne master instrument, local adaptation reviewed by medical advisors, and harmonised coding so a UAE cell reads against a UK or German cell.
- Account-level read-outsWhere the question is commercial, results are cut by hospital group, pharmacy chain or payer so brand teams can act account by account.
BioNixus is the primary-research complement to syndicated audit data: IQVIA tells you what was sold; a BioNixus survey tells you why, by whom, and what would change it.
Why quantitative evidence decides more launches now
Access bars have risen in every priority market. In Saudi Arabia the SFDA Economic Evaluation System, mandatory since 1 July 2025, expects budget-impact and cost-effectiveness inputs at registration; NUPCO centralised tenders set the volume a brand can win in public hospitals; MOHAP, DHA and DOH listing committees in the UAE each ask for local evidence. A physician survey sized for the committee question, not just the brand plan, is now part of the access file.
Syndicated audits report what was sold last quarter but cannot explain the gap between a brand’s share and its potential. Quantitative ATU, demand-estimation and pricing studies close that gap by measuring awareness, perceived differentiation, eligible patient pools and price elasticity among the physicians who actually prescribe in the target accounts.
Launch windows are shorter. With biosimilar and generic entry compressing exclusivity, teams need baseline and six-month tracking waves that read quickly and roll up across countries. Online physician panels in the GCC and Egypt remain thin, so BioNixus blends online, telephone and in-clinic recruitment to reach quota without inflating cost.
Finally, HQ expects comparability. Regional affiliates that commission one-off local surveys struggle to defend findings against global benchmarks. A harmonised instrument fielded by one agency across the GCC, Europe and Asia produces data that global marketing, medical and access teams can use in the same model.
How a BioNixus quantitative study runs
A typical single-country physician survey of 100–150 respondents reports in six to eight weeks; multi-country programmes run in parallel cells.
1. Scoping call and decision brief
A 30-minute call converts the business question into a decision brief: the decision, the metric that would change it, the stakeholder groups that hold the answer and the precision required. This fixes sample size, method and markets before any design work starts.
2. Instrument design and medical review
Questionnaires are drafted with the client’s medical and legal teams, pre-tested with three to five target physicians, and reviewed by a local advisor in each country for terminology, clinical pathway realism and compliance with local promotional codes.
3. Recruitment, screening and verification
Recruitment combines proprietary physician and pharmacist databases, hospital-level outreach and partner panels. Screeners enforce specialty, patient volume and sector quotas; identities are verified against medical councils and licensing bodies before incentives are released.
4. Fieldwork with daily quality control
Fieldwork runs online, by telephone or in clinic depending on specialty reachability. Speeders, straight-liners and inconsistent responders are flagged daily; quotas are monitored by country so no cell closes short.
5. Analysis, modelling and read-out
Weighting, significance testing and advanced analytics (conjoint utilities, segmentation, driver analysis) are documented in a methodology appendix. Findings are presented as decisions, not charts, with a 30/60/90-day action plan and the raw data delivered for internal modelling.
What pharma and medtech teams measure with BioNixus
Demand estimation and forecasting inputs
Eligible patient pool, share of prescriptions a new therapy would capture, and time to adoption by segment, fed directly into launch forecasts.
Pricing and reimbursement research
Van Westendorp price-sensitivity meters, Gabor-Granger demand curves and payer willingness-to-pay studies that set launch price corridors and tender bids.
ATU and brand tracking
Awareness, trial, usage and message recall tracked in waves across GCC, Egypt and European markets so brand teams see movement by country and account.
Message and concept testing
Monadic and sequential-monadic tests of value propositions and detail aids with the physicians the sales force will meet.
Segmentation and targeting
Attitudinal and behavioural segments of prescribers linked to institution type so field teams know which accounts to prioritise.
Medical device and diagnostics adoption
Procurement committee, biomedical engineer and clinician surveys on device preference, switching barriers and tender criteria.
Primary quantitative research vs syndicated audit data
Teams rarely choose between the two; they pair them. The table shows what each answers so the brief lands on the right instrument.
| Dimension | Syndicated / desk / global | BioNixus primary research |
|---|---|---|
| Question answered | What was sold, where, in what volume | Why, by whom, and what would change behaviour |
| Unit of analysis | Pack, molecule, channel | Physician, pharmacist, payer, account |
| Coverage of GCC and Egypt | Retail and partial hospital audit | Public and private hospital, retail and payer stakeholders, bilingual |
| Timing | Monthly or quarterly, retrospective | Scoped to the decision: 6–8 weeks, forward-looking |
| Ownership | Licensed, shared across subscribers | Client-owned data and instrument |
Scope, timelines and pricing
Published pricing: most BioNixus primary research projects fall between $10,000 and $60,000 depending on sample, countries and depth. Qualitative programmes with 20–40 interviews sit toward the lower half of the band; multi-country quantitative studies and mixed-method programmes toward the upper half. A scoping call fixes the design and a costed proposal follows within 48 hours.
Single-country physician surveys of 100–150 respondents typically report in six to eight weeks. Multi-country programmes run in parallel cells with a harmonised master questionnaire; adding a country adds fieldwork cost, not calendar time. BioNixus runs 120+ primary research projects a year (127 in 2025) across 48 countries, with in-house teams in the GCC, Egypt and the UK and vetted fieldwork partners in Europe, the Americas and Asia.
Planning a physician or payer survey?
Primary research, market access & HEOR. A 30-minute scoping call, then a costed proposal within 48 hours.
What happens on the call
- We pin down the decision your research has to support.
- We check feasibility: respondent types, countries and timeline.
- You receive a costed proposal within 48 hours of the call.
More questions on scope, pricing and timelines
What sample size do we need for a physician survey?
It depends on the decision. Directional reads on awareness or preference are reliable at 50–75 specialists per country; pricing, conjoint and segmentation work normally needs 100–200. BioNixus calculates the sample during the scoping call from the precision the decision requires and the specialty’s reachable universe in each market.
Can you reach specialists in Saudi Arabia, the UAE and Egypt online?
Partly. Online panels are thin for many specialties in the GCC and Egypt, so BioNixus blends online invitations with telephone and in-clinic recruitment through its own physician databases and hospital relationships. This keeps quotas achievable and reduces the professional-respondent bias common in panel-only studies.
How do you verify that respondents are real, practising physicians?
Screeners enforce specialty, years in practice and monthly patient volume; identities are checked against medical council and licensing records before incentives are paid; and in-survey consistency checks remove speeders and straight-liners. Verification rates are reported in the methodology appendix.
Do you run conjoint and discrete-choice experiments?
Yes. BioNixus designs choice-based conjoint, MaxDiff and discrete-choice experiments for product-profile, pricing and tender-criteria questions, with simulators delivered so brand teams can test scenarios after the read-out.
How does this complement IQVIA or other syndicated data?
Syndicated audits show sales volumes by pack and channel; they cannot explain prescriber motivation or predict response to a new price or message. BioNixus surveys supply the behavioural and attitudinal layer, cut by the same accounts, so teams can act on the gap between share and potential.
How long does a quantitative study take and what does it cost?
Single-country studies of 100–150 physicians report in six to eight weeks. Published pricing runs from $10,000 to $60,000 depending on countries, sample and analytics; a costed proposal follows the scoping call within 48 hours.